Jasvinder Singh, MD
Interventional Pain Medicine · Maplewood, MNNPI 1619409240
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $3,479 of the $5,503 with a category attached, or 63.2%. Abbott accounts for 68.4% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2022 at $4,219 and has fallen 87.6% since, to $525 in 2024.
Across 39 payments — averaging $141.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Medtronic$757
- Nevro Corp.$240
- Shockwave Medical, Inc$208
- Saluda Medical Americas, Inc.$203
- GRT US Holding, Inc.$117
- plus $212 from 2 others
What the payments were for
- Travel & lodging$3,47963%
- Food & beverage$2,02437%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 22 | $3,767 |
| Medtronic | 10 | $757 |
| Nevro Corp. | 2 | $240 |
| Shockwave Medical, Inc | 1 | $208 |
| Saluda Medical Americas, Inc. | 1 | $203 |
| GRT US Holding, Inc. | 1 | $117 |
| Boston Scientific | 1 | $115 |
| Stryker | 1 | $96 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$3,465
- INTELLIS ADAPTIVESTIM$597
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$208
- Evoke SCS$203
- Omnia$150
- ETERNA$141
- Qutenza$117
How this compares
$5,503 in reported general payments places this provider in the 75th percentile of 26 interventional pain medicine providers in Minnesota.
See all interventional pain medicine providers in Minnesota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 78 | $1,922 |
| Methocarbamol | 53 | $998 |
| Oxycodone Hcl | 23 | $379 |
| Pregabalin | 25 | $314 |
| Tizanidine Hcl | 27 | $250 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Maplewood
- Gregory CrewdsonMaplewood$8K
- Gabriel Pagani-EstevezRochester$179K
- Nima AdimiChaska$114K
- Ryan BirklandRochester$15K
- James ParmeleMaple Grove$13K
- Jason WolffMaple Grove$9K
- Gabriel SmithRochester$5K
- Nicholas CanzanelloRochester$4K
- Ifechi AnyadiohaMankato$4K
- Andrew ClaryWoodbury$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.